Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Butylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 0.73 |
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.43 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.43 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA3 | P07451 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butylamine SCHEMBL15124637 | 1.00 | DNM1 (0.73) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Butylamine SCHEMBL542456 | 1.00 | — | — | |
| Butylamine SCHEMBL25292609 | 1.00 | — | — | |
| Butylamine SCHEMBL122733 | 1.00 | — | — | |
| Butylamine SCHEMBL21751936 | 0.96 | — | — | |
| Butylamine SCHEMBL28509688 | 0.96 | — | — | |
| Butylamine SCHEMBL25333935 | 0.96 | DNM1 (0.69) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Butylamine SCHEMBL25333937 | 0.96 | DNM1 (0.69) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Butylamine SCHEMBL20642114 | 0.96 | — | — | |
| Butylamine SCHEMBL28396296 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208951-A1 | A PROCESS FOR PREPARING NAVAFENTEROL AND INTERMEDIATES THEREOF | GBR LABORATORIES PRIVATE LIMITED (IN) | 2024-06-27 | — | — | US | claimed |
| CN-117567369-A | Sulfatase-based enzymatic chemiluminescent probe and preparation method and application thereof | 中国药科大学 | 2024-02-20 | — | — | CN | claimed |
| CN-115340521-B | Sulfur hydride chemiluminescence probe and preparation method and application thereof | 徐州医科大学 | 2023-09-26 | — | — | CN | claimed |
| CN-109265431-B | Synthesis process of 3-acetyl-10, 11-dihydro-5H-dibenzo [ C, G ] chromen-8 (9H) -one | 江苏苏利精细化工股份有限公司 | 2020-05-26 | — | — | CN | claimed |
| US-10301321-B2 | Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2019-05-28 | — | — | US | claimed |
| CN-109265431-A | 3- acetyl group -10,11- dihydro -5H- dibenzo [C, G] chromene -8(9H) -one synthesis technology | 江苏苏利精细化工股份有限公司 | 2019-01-25 | — | — | CN | claimed |
| US-20180155364-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2018-06-07 | — | — | US | claimed |
| WO-2013179105-A1 | IMPROVED PROCESS FOR PREPARATION OF RILPIVIRINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2013-12-05 | — | — | WO | claimed |
| EP-2379605-A1 | PROCESS FOR BROMINATING BUTADIENE POLYMERS USING ESTER SOLVENT MIXTURES | Dow Global Technologies LLC (US) | 2011-10-26 | — | — | EP | claimed |
| EP-2268676-A1 | PROCESS FOR BROMINATING BUTADIENE/VINYL AROMATIC COPOLYMERS | Dow Global Technologies Inc. (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2010080286-A1 | PROCESS FOR BROMINATING BUTADIENE POLYMERS USING ESTER SOLVENT MIXTURES | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-07-15 | — | — | WO | claimed |
| WO-2009126531-A1 | PROCESS FOR BROMINATING BUTADIENE/VINYL AROMATIC COPOLYMERS | DOW GLOBAL TECHNOLOGIES, INC. (US) | 2009-10-15 | — | — | WO | claimed |
| EP-2054445-A2 | PROCESS FOR BROMINATING BUTADIENE/VINYL AROMATIC COPOLYMERS | Dow Global Technologies Inc. (US) | 2009-05-06 | — | — | EP | claimed |
| WO-2008021417-A2 | PROCESS FOR BROMINATING BUTADIENE/VINYL AROMATIC COPOLYMERS | DOW GLOBAL TECHNOLOGIES, INC. (US) | 2008-02-21 | — | — | WO | claimed |
| US-20260015309-A1 | PROCESS FOR THE SYNTHESIS OF VITAMIN K2 | SYNERGIA LIFE SCIENCES PVT. LTD. (IN) | 2026-01-15 | — | — | US | disclosed |
| EP-4561976-A2 | UROLITHIN AND FLUORENE DERIVATIVES FOR INHIBITING FERROPTOSIS | Vandria SA (CH) | 2025-06-04 | — | — | EP | disclosed |
| EP-4554925-A1 | PROCESS FOR THE SYNTHESIS OF VITAMIN K2 | Synergia Life Sciences Pvt. Ltd (IN) | 2025-05-21 | — | — | EP | disclosed |
| WO-1996011902-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-04-25 | — | — | WO | disclosed |
| WO-1996006822-A1 | ORTHO-SUBSTITUTED AROMATIC ETHER COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR PAIN RELIEF | ZENECA LIMITED (GB) | 1996-03-07 | — | — | WO | disclosed |
| WO-1996003380-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015309-A1 | PROCESS FOR THE SYNTHESIS OF VITAMIN K2 | PROC, TPRKB, KCNK9 | DNM1 4644/4885TSHR 685/4885MEN1 300/4885 |
| US-20240208951-A1 | A PROCESS FOR PREPARING NAVAFENTEROL AND INTERMEDIATES THEREOF | CYP4A11, CYP4F11, XDH | DNM1 4529/4885TSHR 2648/4885MEN1 3773/4885 |
| US-10301321-B2 | Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | CYP3A5, CYP3A43, CYP3A4 | DNM1 748/4885TSHR 4693/4885MEN1 4541/4885 |
| US-20180155364-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CYP3A5, SAMHD1, CYP3A43 | DNM1 1003/4885TSHR 4730/4885MEN1 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.